The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday newspaper round-up: BRICs, Inflation, GlaxoSmithKline...

Tue, 18th Jan 2011 06:33

Goldman Sachs has issued a short-term alert on China and India as inflation rears its ugly head, advising clients to rotate into Wall Street and Old World bourses as a safer bet over coming months."We're not as tactically positive on the BRICs as we have been," said Tim Moe, the bank's chief Asia-Pacific strategist, referring to the quartet of Brazil, Russia, India, and China. "To be frank, we may have held on too long to our overweight position in China last year. We have decided that discretion is the better part of valour and have tactically reduced our weight. Asia is not in the sweet part of the cycle." the Telegraph reports.China has lent more money to other developing countries over the past two years than the World Bank, a stark indication of the scale of Beijing's economic reach and its drive to secure natural resources. China Development Bank and China Export-Import Bank signed loans of at least $110bn (£70bn) to other developing country governments and companies in 2009 and 2010, according to Financial Times research.Goldman Sachs has scrapped an offer to its wealthy clients in the US to participate in a $1.5bn investment in Facebook, dealing a blow to one of the most closely watched private financings for a US company in years. The offer will still be open to investors elsewhere but the bank said that the high level of publicity the plan had generated threatened to put it in breach of US securities laws, which are designed to limit the promotion of private share sales, the FT reports.Inflation is likely to jump to a two-year high today, as economists predict the headline rate will peak soon at more than 5% - raising further questions about whether the Bank of England should raise interest rates faster than expected. Such a move, which could come as early as May, would quickly add about £40 to the average monthly mortgage bill. David Cameron recently said the rate of inflation was "concerning", the Independent reports.European finance ministers have increased their support for a bigger rescue fund for debt-laden eurozone countries, but EU paymaster Germany said there was no rush and it could be March before a package of wider changes would be approved. A two-day monthly Ecofin meeting in Brussels, which started on Monday night, will focus on discussing a boost to the lending power of the European Financial Stability Facility (EFSF), the Telegraph reports.DE Shaw, one of the world's biggest hedge funds, has taken a near £100m short position in Barclays amid concern over the future health of the banking industry. The hedge fund, which has $21bn (£13bn) in assets under management, disclosed that it had built a 0.26% short position. The position is worth £97m after Barclays' shares closed at 306p on Monday, the Telegraph reports.GlaxoSmithKline admitted yesterday that its profits for the final three months of last year will be wiped out by legal costs relating to its Avandia diabetes drug, which has been linked to heart attacks and strokes in users. The company will record a £2.2bn legal charge as it settles further claims linked to the drug that was once its second-best-selling product ? and hundreds more American lawsuits are still in the pipeline, the Times reports.The new chief executive of a quango targeted for cuts has accepted a pay package about £61,000 smaller than his predecessor in a move that reduces his pay below that of the Prime Minister. Bill Galvin, who yesterday was promoted to be chief executive of The Pensions Regulator ? one of hundreds of quangos facing cuts ? will receive base pay of £138,000, which is £4,500 less than David Cameron. It represents a cut of about £39,000, or 22%, on the £175,000-179,000 base salary paid to his predecessor Tony Hobman, who left in May, the Times reports.BP's £10bn share swap with Russia's Rosneft could signal the end of its long-troubled relationship with Washington, according to leading shareholders. The landmark deal, formalised on Friday, also makes it more likely that the oil group will consider breaking itself up along geographical lines, several top investors said. BP could spin off a stronger Russian business and sell its North American division, either in part or as a whole, they said. While strengthening ties with the Kremlin carries political risks, shareholders said it could help to stabilise TNK-BP, BP's turbulent existing joint venture in Russia, over the longer term, the Times reports.
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.